Global Self monitoring Blood Glucose Devices Market Size By Type (Strips, Glucose Meter), By Application (Public Hospital, Private Hospital), By Region, And Segment Forecasts, 2023 to 2032

The Global Self-Monitoring Blood Glucose (SMBG) Devices Market was valued at USD 12.9 billion in 2023 and is projected to reach USD 20.5 billion by 2031, growing at a CAGR of 6.0% during the forecast period from 2023 to 2031. The rising prevalence of diabetes, increasing awareness about personal health monitoring, and technological innovations in glucose monitoring systems are significantly boosting the market. The shift towards home-based and real-time glucose monitoring, supported by user-friendly, compact, and digital devices, is reshaping the diabetes care landscape globally.

Drivers:

1. Growing Prevalence of Diabetes:

A surge in both Type 1 and Type 2 diabetes worldwide is the primary driver of SMBG device adoption. Increased awareness around glycemic control and complications associated with unmanaged diabetes are encouraging patients to adopt personal monitoring solutions.

2. Increasing Demand for At-Home Monitoring Solutions:

Post-pandemic, consumers are more inclined towards self-care and home diagnostics. SMBG devices offer patients real-time data, empowering them to manage their condition more independently, which reduces the burden on healthcare infrastructure.

3. Technological Innovations:

Continuous advances such as Bluetooth connectivity, smartphone integration, cloud-based monitoring, and wearable blood glucose monitors are enhancing user experience, accuracy, and adherence to diabetes management routines.

Restraints:

1. High Cost of Advanced Devices:

Though demand for smart and continuous monitoring systems is increasing, the high cost of advanced SMBG devices limits their adoption, especially in low- and middle-income countries.

2. Inaccuracy in User Operation:

Incorrect usage, calibration errors, or failure to follow proper testing protocols can yield unreliable readings, which can potentially hinder effective disease management.

Opportunity:

1. Untapped Potential in Emerging Economies:

Asia-Pacific and Latin America present considerable growth potential due to their large diabetic population, increasing healthcare investments, and rising awareness about chronic disease management.

2. Expansion of Digital Health Ecosystems:

Integration of SMBG devices with mobile apps and cloud platforms allows real-time data sharing with healthcare providers, facilitating telemedicine and remote monitoring solutions.

Market by System Type Insights:

By system type, the Blood Glucose Meters (BGMs) segment dominated the market in 2023. BGMs are widely adopted due to their affordability, ease of use, and immediate results. However, the Continuous Glucose Monitoring (CGM) segment is expected to grow at the fastest pace, owing to growing interest in non-invasive and real-time glucose tracking among Type 1 diabetic patients and tech-savvy individuals.

Market by End-use Insights:

In 2023, the Home Care Settings segment held the largest share of the market. Increased demand for personal health monitoring and convenience in daily glucose tracking have propelled this segment’s growth. Conversely, the Hospitals & Clinics segment remains critical for initial diagnosis, emergencies, and regular evaluations, supporting substantial revenue share.

Market by Regional Insights:

North America led the global market in 2023, driven by a high diabetic population, well-established healthcare infrastructure, and early adoption of digital health solutions. Meanwhile, Asia-Pacific is anticipated to witness the highest growth during the forecast period due to increasing diabetes prevalence, urbanization, and supportive government programs aimed at enhancing disease management.

Competitive Scenario:

Leading companies in the global SMBG devices market include Abbott Laboratories, F. Hoffmann-La Roche Ltd., Dexcom Inc., LifeScan Inc., Ascensia Diabetes Care Holdings AG, Medtronic plc, Arkray Inc., Ypsomed Holding AG, Bionime Corporation, and Senseonics Holdings, Inc. These firms are focusing on strategic collaborations, AI-based device enhancements, and expansion into underserved regions.

Scope of Work – Global Self-Monitoring Blood Glucose Devices Market

Report Metric Details

Market Size (2023) USD 12.9 Billion

Projected Market Size (2031) USD 20.5 Billion

CAGR (2023–2031) 6.0%

Market Segments System Type (BGM, CGM), End-use (Home Care, Hospitals)

Growth Drivers Rising diabetes prevalence, demand for home-based care

Opportunities Emerging markets, digital integration of SMBG platforms

Key Market Developments:

2023: Abbott Laboratories launched the Libre 4 system, a next-gen continuous glucose monitor featuring real-time alerts and improved sensor lifespan.

2024: Dexcom introduced a compact wearable CGM device targeting adolescent and pediatric populations, emphasizing comfort and precision.

2025: Ascensia Diabetes Care partnered with a leading AI healthcare platform to integrate real-time blood glucose insights into a virtual diabetes coaching app.

FAQs:

1) What is the current market size of the Global Self-Monitoring Blood Glucose Devices Market?

The market was valued at USD 12.9 billion in 2023.

2) What is the major growth driver of the Global Self-Monitoring Blood Glucose Devices Market?

The major driver is the rising prevalence of diabetes and the growing demand for personal glucose monitoring solutions.

3) Which is the largest region during the forecast period in the Global Self-Monitoring Blood Glucose Devices Market?

North America is projected to maintain dominance throughout the forecast period.

4) Which segment accounted for the largest market share in the Global Self-Monitoring Blood Glucose Devices Market?

The Blood Glucose Meters (BGM) segment held the largest share in 2023.

5) Who are the key market players in the Global Self-Monitoring Blood Glucose Devices Market?

Major players include Abbott Laboratories, Roche, Dexcom, LifeScan, and Ascensia Diabetes Care.